Compare 10X Genomics Inc (TXG) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Unilever plc — how do they compare? 10X Genomics Inc trades at $81.93 (market cap $10.07B), while Unilever plc trades at $61.98 (market cap $131.63B). The key difference: Unilever plc is far larger — about 13.1× 10X Genomics Inc's market cap, and Unilever plc pays a 3.43% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Unilever plc for 112 Days on average.
| TXG | UL | |
|---|---|---|
Market Cap | $10.07B | $131.63B |
Volume | 5,657,286 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $97.74 | $74.59 |
52-Week Low | $11.48 | $55.05 |
Typical Hold Time | 92 Days | 112 Days |
Enterprise Value | $9.59B | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Unilever (UL) trades at $61.98, up 1.64% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is mixed with 24% buy ratings amid ongoing business restructuring including the planned McCormick food division sale.
UL offers defensive exposure with emerging market growth potential but faces execution risks from portfolio streamlining. The stock presents moderate valuation (P/E 21.59) with cash flow stability, though recent earnings underperformance and regulatory scrutiny on the McCormick deal warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
